查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1523147

癌症治療 ADC（抗體藥物複合體）市場報告：到 2030 年的趨勢、預測和競爭分析

Cancer Antibody Drug Conjugates Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

癌症治療 ADC（抗體藥物複合體）的趨勢和預測

2030年，全球癌症藥物ADC市場預計將達到209億美元，2024年至2030年的複合年成長率為15.6%。該市場的主要驅動力是全球癌症發病率不斷上升、偶聯技術和抗體工程的持續進步以及研發 (R&D) 支出的增加。全球抗癌藥物ADC市場前景廣闊，血液學、乳癌、卵巢、肺癌、皮膚癌、腦癌等市場充滿機會。

癌症治療 ADC（按細分市場）

該研究按產品、應用、技術、最終用途行業和地區對全球癌症藥物 ADC 進行了預測。

癌症藥物ADC市場洞察

Lucintel 預測，由於癌症發生率的增加以及 ADC 在癌症治療中的使用，kadcyla 將在預測期內經歷最高的成長。

在這個市場中，由於全球乳癌盛行率不斷上升，乳癌將繼續成為最大的細分市場。

由於主要行業參與者加強戰略力度和有利的地方政府計劃，預計亞太地區將在預測期內實現最高成長。

常問問題

Q1.市場規模為：

A1. 至2030年，全球癌症藥物ADC市場預計將達到209億美元。

Q2.市場成長預測是多少：

A2. 2024年至2030年，全球癌症藥物ADC市場預計將以15.6%的複合年成長率成長。

Q3.影響市場成長的主要促進因素是：

A3. 該市場的主要驅動力是全球癌症發生率的增加、偶聯技術和抗體工程的持續發展以及研發支出的增加。

Q4.市場的主要細分市場是：

A4. 癌症 ADC 市場前景廣闊，血癌、乳癌、卵巢癌、肺癌、皮膚癌和腦癌市場充滿機會。

Q5.市場的主要企業是：

A5. 主要抗癌藥物ADC公司如下：

  • Seagen
  • Takeda Pharmaceutical Company
  • AstraZeneca
  • F. Hoffmann-La Roche
  • Pfizer
  • Gilead Sciences
  • Daiichi Sankyo Company
  • GlaxoSmithKline
  • Astellas Pharma
  • ADC Therapeutics

Q6.未來最大的細分市場是什麼？

A6.Lucintel預測，由於癌症發生率上升以及ADC在癌症治療中的使用，kadcyla將在預測期內經歷最高成長。

Q7. 未來五年預計哪些地區的市場成長最大？

由於主要產業參與者加強戰略力度和有利的地方政府計劃，預計 A7.APAC 將在預測期內實現最高成長。

Q8. 可以客製化報告嗎？

A8. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章 全球抗癌藥物ADC市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球癌症治療ADC市場趨勢（2018-2023）與預測（2024-2030）
  • 全球癌症藥物 ADC 市場（按產品）
    • Kadcyla
    • Enhertu
    • Adcetris
    • Padcev
    • Trodelvy
    • Polivy
    • 其他
  • 全球癌症藥物 ADC 市場（按應用）
    • 血癌
    • 乳癌
    • 卵巢癌
    • 肺癌
    • 皮膚癌
    • 腦腫瘤
    • 其他
  • 按技術分類的全球癌症藥物 ADC 市場
    • 切割類型
    • 非切削型
  • 按最終用途行業分類的全球癌症藥物 ADC 市場
    • 醫院
    • 專科診所
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球癌症藥物 ADC 市場（按地區）
  • 北美抗癌藥物ADC市場
  • 歐洲抗癌藥物ADC市場
  • 亞太地區抗癌藥物ADC市場
  • 其他地區抗癌藥物ADC市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
  • 全球抗癌藥物ADC市場新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球抗癌藥物ADC市場產能
    • 全球抗癌藥物ADC市場併購及合資
    • 認證和許可

第7章主要企業概況

  • Seagen
  • Takeda Pharmaceutical Company
  • AstraZeneca
  • F. Hoffmann-La Roche
  • Pfizer
  • Gilead Sciences
  • Daiichi Sankyo Company
  • GlaxoSmithKline
  • Astellas Pharma
  • ADC Therapeutics
簡介目錄

Cancer Antibody Drug Conjugates Trends and Forecast

The future of the global cancer antibody drug conjugates market looks promising with opportunities in the blood cancer, breast cancer, ovary cancer, lung cancer, skin cancer, and brain tumor markets. The global cancer antibody drug conjugates market is expected to reach an estimated $20.9 billion by 2030 with a CAGR of 15.6% from 2024 to 2030. The major drivers for this market are growing incidence of cancer worldwide, continuous developments in conjugation technology and antibody engineering, and increased spending on research and development (R&D) initiatives.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Cancer Antibody Drug Conjugates by Segment

The study includes a forecast for the global cancer antibody drug conjugates by product, application, technology, end use industry, and region.

Cancer Antibody Drug Conjugates Market by Product [Shipment Analysis by Value from 2018 to 2030]:

  • Kadcyla
  • Enhertu
  • Adcetris
  • Padcev
  • Trodelvy
  • Polivy
  • Others

Cancer Antibody Drug Conjugates Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Blood Cancer
  • Breast Cancer
  • Ovary Cancer
  • Lung Cancer
  • Skin Cancer
  • Brain Tumor
  • Others

Cancer Antibody Drug Conjugates Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

  • Cleavable
  • Non-Cleavable

Cancer Antibody Drug Conjugates Market by End Use Industry [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Others

Cancer Antibody Drug Conjugates Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Cancer Antibody Drug Conjugates Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer antibody drug conjugates companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer antibody drug conjugates companies profiled in this report include-

  • Seagen
  • Takeda Pharmaceutical Company
  • AstraZeneca
  • F. Hoffmann-La Roche
  • Pfizer
  • Gilead Sciences
  • Daiichi Sankyo Company
  • GlaxoSmithKline
  • Astellas Pharma
  • ADC Therapeutics

Cancer Antibody Drug Conjugates Market Insights

Lucintel forecasts that kadcyla is expected to witness the highest growth over the forecast period due to growth in the incidence of cancer and the usage of ADCs in cancer therapy.

Within this market, breast cancer will remain the largest segment due to increasing prevalence of breast cancer across the globe.

APAC is expected to witness the highest growth over the forecast period due to growing strategic efforts by major industry participants and advantageous regional government programs.

Features of the Global Cancer Antibody Drug Conjugates Market

Market Size Estimates: Cancer antibody drug conjugates market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cancer antibody drug conjugates market size by product, application, technology, end use industry, and region in terms of value ($B).

Regional Analysis: Cancer antibody drug conjugates market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product, application, technology, end use industry, and regions for the cancer antibody drug conjugates market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer antibody drug conjugates market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the cancer antibody drug conjugates market size?

Answer: The global cancer antibody drug conjugates market is expected to reach an estimated $20.9 billion by 2030.

Q2. What is the growth forecast for cancer antibody drug conjugates market?

Answer: The global cancer antibody drug conjugates market is expected to grow with a CAGR of 15.6% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the cancer antibody drug conjugates market?

Answer: The major drivers for this market are growing incidence of cancer worldwide, continuous developments in conjugation technology and antibody engineering and increased spending on research and development (R&D) initiatives.

Q4. What are the major segments for cancer antibody drug conjugates market?

Answer: The future of the cancer antibody drug conjugates market looks promising with opportunities in the blood cancer, breast cancer, ovary cancer, lung cancer, skin cancer, and brain tumor markets.

Q5. Who are the key cancer antibody drug conjugates market companies?

Answer: Some of the key cancer antibody drug conjugates companies are as follows:

  • Seagen
  • Takeda Pharmaceutical Company
  • AstraZeneca
  • F. Hoffmann-La Roche
  • Pfizer
  • Gilead Sciences
  • Daiichi Sankyo Company
  • GlaxoSmithKline
  • Astellas Pharma
  • ADC Therapeutics

Q6. Which cancer antibody drug conjugates market segment will be the largest in future?

Answer: Lucintel forecasts that kadcyla is expected to witness the highest growth over the forecast period due to growth in the incidence of cancer and the usage of ADCs in cancer therapy.

Q7. In cancer antibody drug conjugates market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness the highest growth over the forecast period due to growing strategic efforts by major industry participants and advantageous regional government programs.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the cancer antibody drug conjugates market by product (kadcyla, enhertu, adcetris, padcev, trodelvy, polivy, and others), application (blood cancer, breast cancer, ovary cancer, lung cancer, skin cancer, brain tumor, and others), technology (cleavable and non-cleavable), end use industry (hospitals, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cancer Antibody Drug Conjugates Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Cancer Antibody Drug Conjugates Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Cancer Antibody Drug Conjugates Market by Product
    • 3.3.1: Kadcyla
    • 3.3.2: Enhertu
    • 3.3.3: Adcetris
    • 3.3.4: Padcev
    • 3.3.5: Trodelvy
    • 3.3.6: Polivy
    • 3.3.7: Others
  • 3.4: Global Cancer Antibody Drug Conjugates Market by Application
    • 3.4.1: Blood Cancer
    • 3.4.2: Breast Cancer
    • 3.4.3: Ovary Cancer
    • 3.4.4: Lung Cancer
    • 3.4.5: Skin Cancer
    • 3.4.6: Brain Tumor
    • 3.4.7: Others
  • 3.5: Global Cancer Antibody Drug Conjugates Market by Technology
    • 3.5.1: Cleavable
    • 3.5.2: Non-cleavable
  • 3.6: Global Cancer Antibody Drug Conjugates Market by End Use Industry
    • 3.6.1: Hospitals
    • 3.6.2: Specialty Clinics
    • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Cancer Antibody Drug Conjugates Market by Region
  • 4.2: North American Cancer Antibody Drug Conjugates Market
    • 4.2.1: North American Cancer Antibody Drug Conjugates Market by Product: Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, and Others
    • 4.2.2: North American Cancer Antibody Drug Conjugates Market by Application: Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, and Others
  • 4.3: European Cancer Antibody Drug Conjugates Market
    • 4.3.1: European Cancer Antibody Drug Conjugates Market by Product: Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, and Others
    • 4.3.2: European Cancer Antibody Drug Conjugates Market by Application: Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, and Others
  • 4.4: APAC Cancer Antibody Drug Conjugates Market
    • 4.4.1: APAC Cancer Antibody Drug Conjugates Market by Product: Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, and Others
    • 4.4.2: APAC Cancer Antibody Drug Conjugates Market by Application: Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, and Others
  • 4.5: ROW Cancer Antibody Drug Conjugates Market
    • 4.5.1: ROW Cancer Antibody Drug Conjugates Market by Product: Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, and Others
    • 4.5.2: ROW Cancer Antibody Drug Conjugates Market by Application: Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Cancer Antibody Drug Conjugates Market by Product
    • 6.1.2: Growth Opportunities for the Global Cancer Antibody Drug Conjugates Market by Application
    • 6.1.3: Growth Opportunities for the Global Cancer Antibody Drug Conjugates Market by Technology
    • 6.1.4: Growth Opportunities for the Global Cancer Antibody Drug Conjugates Market by End Use Industry
    • 6.1.5: Growth Opportunities for the Global Cancer Antibody Drug Conjugates Market by Region
  • 6.2: Emerging Trends in the Global Cancer Antibody Drug Conjugates Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Cancer Antibody Drug Conjugates Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cancer Antibody Drug Conjugates Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Seagen
  • 7.2: Takeda Pharmaceutical Company
  • 7.3: AstraZeneca
  • 7.4: F. Hoffmann-La Roche
  • 7.5: Pfizer
  • 7.6: Gilead Sciences
  • 7.7: Daiichi Sankyo Company
  • 7.8: GlaxoSmithKline
  • 7.9: Astellas Pharma
  • 7.10: ADC Therapeutics